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ABSTRACT: Patients with fixed airflow limitation are grouped under the heading of
chronic obstructive pulmonary disease (COPD). The authors investigated whether
COPD patients have distinct functional, radiological and sputum cells characteristics
depending on the presence or absence of emphysema.
Twenty-four COPD outpatients, 12 with and 12 without emphysema on high-
resolution computed tomography scan of the chest, were examined. Patients underwent
chest radiography, pulmonary function tests and sputum induction and analysis.
Subjects with documented emphysema had lower forced expiratory volume in one
second (FEV1), FEV1/forced vital capacity ratio, and lower carbon monoxide diffusion
constant (KCO), compared with subjects without emphysema. Chest radiograph score of
emphysema was higher, chest radiograph score of chronic bronchitis was lower, and the
number of sputum lymphocytes was increased in patients with emphysema, who also
showed a negative correlation between KCO and pack-yrs.
Chronic obstructive pulmonary disease patients with emphysema, documented by
high-resolution computed tomography scan, have a different disease phenotype
compared with patients without emphysema. Identification of chronic obstructive
pulmonary disease-related phenotypes may improve understanding of the natural
history and treatment of the disease.
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Chronic obstructive pulmonary disease (COPD) is char-
acterised by the progressive development of airflow limitation
that is not fully reversible [1]. Chronic airflow limitation is
caused by a mixture of small airways inflammatory disease,
obstructive bronchiolitis and parenchymal destruction, and
emphysema, the relative contributions of which vary from
person to person [2].
Chronic inflammation causes remodelling and narrowing of
the small airways and, theoretically, it responds to pharma-
cological treatment. Destruction of the lung parenchyma
leads to the loss of alveolar attachments to the small airways
and decreases lung elastic recoil. These changes, which are
considered to be unresponsive to pharmacological treatment,
diminish the ability of the airways to remain open during
expiration.
COPD has a variable natural history and not all individuals
follow the same course and have the same response to
therapy. Patients with emphysema have the lowest survival
rate and the highest rate of decline in pulmonary function
among COPD patients [3]. Thus, it is clinically relevant to
detect, in the diagnostic work-up of patients with COPD,
individuals with emphysema, possibly by using noninvasive
methods. Although it has become increasingly clear that lung
computed tomography (CT), especially when performed with
thin-section, high-resolution techniques, is the most accurate
imaging method for detecting the extent and severity of
emphysema [4], lung function and chest radiography are
invariably obtained in the clinical assessment of COPD.
Recently, the application of sputum induction and refined
methods of sputum examination have provided the opportu-
nity to examine cell and molecular markers of airway
inflammation in COPD [5], contributing to the characterisa-
tion of lung inflammation in the disease [6, 7].
The aim of this study was to investigate, by using classical
diagnostic tests, such as lung function tests, radiological
examination and sputum analysis, whether COPD patients
with documented emphysema at high-resolution computed
tomography (HRCT) of the chest have a different disease
phenotype compared with COPD patients without emphysema.
Subjects and methods
Subjects
COPD patients (n=24) with fixed airflow limitation, i.e.
forced expiratory volume in one second (FEV1) v70% of
predicted values and FEV1/forced vital capacity (FVC) ratio
v70%, were examined both before and after 200 mg of inhaled
salbutamol (table 1). Chronic bronchitis was defined as cough
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and sputum production occurring on most days of the month
for at least 3 months per year, during the 2 yrs before the
study [2]. All subjects were recruited from the outpatient clinic
of the Section of Respiratory Diseases of the University of
Ferrara, Ferrara, Italy. The Ethics Committee of the University
Hospital of Ferrara approved the study and all patients gave
their written informed consent. COPD was diagnosed accord-
ing to the criteria recommended by the European Respiratory
Society [8]. All patients were in stable conditions at the time
of the study and free from acute exacerbations of symptoms
and upper respiratory tract infections in the 2 months preced-
ing the study.
Study design
Emphysema was characterised using HRCT technique and
a visual score w10 indicated emphysema [9]. Each patient
underwent medical history, physical examination, pulmonary
function tests, chest radiography, CT, skin-prick tests, induced
sputum, and a1-antitrypsin measurement, since three of the
patients were nonsmokers.
Pulmonary function studies
In each patient, lung volumes (Biomedin, Padova, Italy),
the carbon monoxide diffusion constant (KCO), by the single-
breath technique, end-exhaled nitric oxide (NO) (Nitric oxide
A 280 analyser; Sievers, Boulder, CO, USA), arterial oxygen
(Pa,O2) and carbon dioxide tension (Pa,CO2) (Instrumenta-
tions Laboratories, Milan, Italy) were measured as described
previously [8], according to published guidelines [10–12].
Chest radiography
Chest radiographs (postero-anterior and lateral) were
obtained with the patients in an upright position, holding
their breath at full inspiration. A standard 2 m focus-to-film
distance was used. Exposure time was kept as short as
possible to reduce motion blurring and was usually within
0.05 s. A fine lead grid (grid ratio 6) was used to reduce
scattered X-rays, thereby enhancing film resolution. Chest
radiographs were obtained within 48 h of pulmonary function
studies and prior to the sputum inductions. Chronic bron-
chitis and emphysema scores, ranging 0–16, were calculated
as described previously [9, 13]. Emphysema and chronic
bronchitis scores have proved highly reproducible among
different observers [9, 13].
Computed tomography
HRCT scans were performed at suspended full inspiration
on a TOMOS 7000 scanner (Philips, Einthoven, The Nether-
lands), as described previously [9]. No contrast medium was
infused. Technical parameters were 1 mm collimation, 120 kV
peak, 160 mA, and 3-s scanning time. A visual score of
emphysema was derived according to the method of SAKAI
et al. [14] and a cumulative score of emphysema, ranging 0–72
was obtained, as described previously [9].
Induced sputum
Sputum was collected after bronchodilator inhalation and
analysed as described previously [8]. To make the procedure
safer, sputum was induced and spirometric measurements
were performed as reported previously [15]. Increasing concen-
trations of hypertonic saline were nebulised with an ultrasonic
nebuliser (Mistogen EN 145 electronic nebuliser; Mistogen
Equipment Co., Oakland, CA, USA).
Atopic status
Skin-prick tests to 12 common aeroallergens were per-
formed according to a standard protocol [8].
a1-antitrypsin
A peripheral blood sample was drawn and the serum was
separated. Antibodies against human a1-antitrypsin were
added to the serum and the intensity of the light diffused by
suspended particles, resulting from the formation of the
antigen/antibody complex, was measured with a nephelo-
metric method (Beckman Instruments, Milan, Italy).
Statistical analysis
Group data are expressed as mean¡SEM or as median
and interquartile range when appropriate. Differences between
groups were analysed using the Mann-Whitney U-test and
Bonferroni9s correction was applied when indicated. Categori-
cal values were analysed using Fisher9s exact test. Spearman9s
rank correlation test was used to examine the association
between lung and radiological data and cigarette smoking and/
or sputum cells. To define the predictive value of the variables
analysed, receiver-operating characteristic (ROC) curve analy-
sis was performed for a comparison of ranked variables. The
area under the ROC curves was determined and a value of
w0.80 was accepted as indicating good discrimination [16].
ROC curve analysis also allowed selection of the best cut-off
Table 1. – Characteristics of the chronic obstructive pul-
monary disease (COPD) patients divided according to the
presence or absence of emphysema on high-resolution com-
puted tomography examination#
Characteristic/pulmonary
function response
Emphysema No
emphysema
Age yrs 68¡2 68¡2
Sex M:F 11:1 11:1
Smoking history pack-yrs 29¡6 36¡7
Body mass index 28¡1.4 26¡0.8
Treatment
Inhaled steroids n (%) 11 (91.6) 7 (58.3)
Inhaled bronchodilators n (%)
Short-acting 9 (75) 7 (58.3)
Long-acting 10 (83.3) 8 (66.6)
Theophylline 4 (33.3) 0 (0)
Positive skin-prick test n (%) 2 (16.6) 4 (33.3)
FEV1 % pred pre-bronchodilator 38¡3} 58¡3
FEV1/FVC % pre-bronchodilator 40.69¡3.3} 54.68¡2.3
RV % pred 129¡8 111¡10
TLC % pred 98¡4 95¡4
IC % pred 78.6¡4.5} 104.2¡4.8
FRC % pred 112¡6* 95¡7
KCO % pred 48¡8* 71¡7
DFEV1 post-bronchodilator mL 120¡25 141¡28
DFEV1 post-bronchodilator % pred 4.3¡0.9 5.4¡1.1
Data are presented as mean¡SEM. M: male; F: female; FEV1:
forced expiratory volume in one s; % pred: % predicted; FVC:
forced vital capacity; RV: residual volume; TLC: total lung
capacity; IC: inspiratory capacity; FRC: functional residual
capacity; KCO: carbon monoxide diffusion constant. #: score
w10 indicated emphysema. *: pv0.05 versus COPD patients
with no emphysema; }: pv0.005 versus COPD patients with no
emphysema.
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point of the variables studied by analysing their sensitivity
versus one minus specificity. A p-value ofv0.05 was accepted as
significant.
Results
Clinical findings
Table 1 shows the characteristics of the subjects examined.
There was no significant difference in age, smoking history
and body mass index between COPD patients with emphysema
and patients with no emphysema. In all subjects, a1-antitrypsin
values were within the normal range (83–199 mg?dL-1). Dys-
pnoea, graded according to the Medical Research Council
dyspnoea scale [17], was mild and similar in the two groups.
Three of the 12 COPD patients with and eight of the 12
without emphysema had symptoms of chronic bronchitis.
Pulmonary function findings
There was no significant difference in total lung capacity
(TLC; % pred), exhaled NO, arterial blood gases and res-
ponse to inhaled salbutamol between the COPD patients with
and without emphysema (table 1). Emphysema patients had a
significantly lower FEV1 (% pred), FEV1/FVC ratio (%) and
KCO (% pred) than patients with no emphysema. For similar
values of TLC in the two groups, inspiratory capacity (IC; % pred)
was significantly lower, whereas functional residual capacity
(FRC; % pred) was significantly higher in COPD patients with
emphysema, indicating greater pulmonary hyperinflation.
Residual volume (RV; % pred) was higher (p=0.09) in the
emphysema group. In this group, a negative correlation was
found between KCO and cigarettes smoked (r=-0.83; pv0.01).
Chest radiography
As expected from the selection criteria, COPD patients with
emphysema had a significantly higher chest radiograph score
of emphysema (7.5 (4.5–10) versus 2 (0.5–3), pv0.001; fig. 1)
and a lower chest radiograph score of chronic bronchitis (3
(2–5.5) versus 6 (5.5–5.7); pv0.005; fig. 1) than patients with
no emphysema.
Sputum findings
Patients with emphysema had more sputum lymphocytes
than patients with no emphysema. No other significant
differences were observed (table 2). When all COPD patients
were considered together, sputum lymphocytes correlated
negatively with IC % pred (r=-0.46, pv0.05) and positively,
albeit not to a significant extent, with the HRCT score of
emphysema (r=0.40, p=0.06). In emphysematous patients, a
positive correlation was found between the HRCT score of
emphysema and sputum neutrophils (r=0.60, pv0.05; fig. 2).
Receiver-operating characteristic curve analysis
FEV1, chest radiograph score of emphysema and sputum
lymphocytes were shown to be the best predictive factors of
emphysema. For FEV1 % pred, the area under the ROC
curves was 0.89, for emphysema score it was 0.90, and for the
percentage of lymphocytes in sputum it was 0.81. For FEV1
% pred, the best cut-off point was 49% pred, which had
a sensitivity of 0.83 and a specificity of 0.83. For the
chest radiograph score of emphysema, the best cut-off
point was 4.0, which had a sensitivity of 0.75 and a specificity
of 0.80. For sputum lymphocytes, the best cut-off point
was 1%, which had a sensitivity of 0.67 and a specificity of
0.83.





	
 
	








	






	

	


Fig. 1. – Chest radiograph scores of emphysema ($) and chronic
bronchitis (#) in chronic obstructive pulmonary disease patients,
divided according to the presence or absence of emphysema. The
horizontal solid bars indicate the median values for each group. ***:
pv0.001; #: pv0.005.
Table 2. – Sputum cells in chronic obstructive pulmonary
disease (COPD) patients divided according to the presence
or absence of emphysema on high-resolution computed
tomography examination
Cells COPD patients
with emphysema
COPD patients with
no emphysema
Total nonsquamous
cells 16104?mL-1
48 (23–111) 60 (17–359)
Macrophages % 30.6 (15.0–46.3) 10.2 (4.7–28.0)
Neutrophils % 64.9 (49.6–82.0) 83.6 (65.5–91.4)
Eosinophils % 2.4 (1–3) 2.5 (1.2–6.3)
Lymphocytes % 1.5 (0.7–3.5)* 0.2 (0–1.0)
Data are presented as median (interquartile range). *: pv0.05
versus COPD patients with no emphysema.
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Fig. 2. – Relationship between high-resolution computed tomography
(HRCT) score of emphysema and percentage of sputum neutrophils
(Spearman9s rank correlation: pv0.05, r=0.60) in chronic obstructive
pulmonary disease patients with emphysema.
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Discussion
In this study, the authors have shown that patients with
fixed airflow limitation (COPD) have a different disease pheno-
type, depending on the presence or absence of emphysema on
chest HRCT. Patients were selected on the basis of functional
criteria, i.e. FEV1 v70% pred and FEV1/FVC ratio v70%
both before and after inhaled bronchodilator. These inclusion
criteria were used as they define most of the COPD patients
involved. COPD subjects with emphysema had lower FEV1,
lower FEV1/FVC ratio, lower KCO, higher chest radiograph
scores of emphysema, lower chest radiograph scores of
chronic bronchitis, and an increased number of lymphocytes
in induced sputum.
These findings of a higher degree of airflow obstruction in
patients with emphysema are in agreement with the results of
previous studies that focused on the relationship between
severity and extent of emphysema and lung function data
[18–22]. By contrast, these findings may appear to conflict
with those of FLETCHER et al. [23], who found no differences
in clinical and lung function features between emphysema
and chronic bronchitis patients. However, they examined a
different population: patients were younger, 20% exhibited
reversible airflow limitation after inhaled bronchodilator, and
the majority had a history of wheezing.
In the present study, a reduction in KCO was found in
COPD patients with emphysema. The reduction of CO diffus-
ing capacity is a physiological abnormality known to be
associated with pulmonary emphysema, and it has been
shown to correlate with the extent of emphysema [24]. In
emphysematous patients, a negative correlation between KCO
and pack-yrs was also observed, which supports and extends
the findings of other studies [25, 26] that have shown a
negative correlation between lung function and pack-yrs even
in asymptomatic subjects [26]. The emphysematous subjects
in this study exhibited baseline values of IC and FRC smaller
and greater, respectively, than those of patients with no
emphysema. As baseline TLC was not different between the
two groups, these data reflect a greater pulmonary hyperin-
flation in emphysematous patients. In these patients, RV and
TLC were higher, but not significantly so, thus indicating that
subjects with emphysema do not have a pure emphysema
phenotype and, therefore, lack the fairly uniform pattern of
abnormal pulmonary function tests characteristic of emphy-
sema. The lack of significant differences in these variables,
however, does not exclude meaningful differences.
In the present COPD patients, the distinction between
emphysema and no emphysema on the HRCT was based on a
cut-off of 10 of the applied visual score, which ranged from
0–72. According to previous findings [9], the authors were
confident that an HRCT score of emphysema that did not
exceed 14% of the maximal score obtainable, was compatible
with no or with only trivial emphysema.
With regard to imaging tests, it has been demonstrated that
conventional chest radiography is useful in the clinical
evaluation of emphysema [9]. The fact that, in this study, a
higher chest radiograph score of emphysema and a lower
score of chronic bronchitis were present in patients with
emphysema, confirms that this examination is useful to
discriminate the two phenotypes, i.e. emphysema and no
emphysema. When all the patients were considered together,
chest radiograph scores of chronic bronchitis showed a
negative correlation with the HRCT emphysema score (data
not shown), suggesting that the features of bronchial and/or
bronchiolar inflammation are predominant in patients with
no emphysema. In this study, symptoms of chronic bronchitis
were present in the majority of patients without emphysema,
but only in three subjects with emphysema, confirming that
hypersecretion of mucus is present more in patients with no
or trivial emphysema [22]. Three subjects without emphy-
sema on HRCT scan and without symptoms of chronic bronchitis
were also observed. These subjects had a high radiograph
score of chronic bronchitis, 6.5, 5.5 and 8.5 (scores ranging
1.5–8.5), suggesting that chest radiography detects bronchial
and/or bronchiolar inflammation better than the symptoms.
Another possible explanation for this lack of relationship
between symptoms and chest radiograph is a different time
course for the two events, with early radiological changes
later followed by symptoms.
This study, using induced sputum, demonstrated a slight
but significant increase in the number of sputum lymphocytes
in patients with emphysema. No differences were observed in
other sputum inflammatory cells, supporting the evidence that
these patients did not have a pure component of lung paren-
chymal destruction, i.e. a pure emphysema phenotype, and
also an airway inflammatory component. Lymphocytes, parti-
cularly CD8z cytolytic T-cells, have been recognised recently
as the predominant cells in the alveolar wall of smokers with
emphysema [27]. The results, obtained by a noninvasive
method, such as sputum induction, confirm this finding. More-
over, a negative correlation was found between sputum lympho-
cytes and IC, which typically decreases in emphysema due to
pulmonary hyperinflation. Taken together, all the above data
suggest that lymphocytes are the inflammatory cells best
associated with emphysema and they may be obtained by
sputum induction. Therefore, it could be useful to introduce
this noninvasive method into the regular work-up of COPD
patients, given that it is also simple and safe [28]. Finally,
regarding sputum differential cell counts, it should also be
noted that there was a correlation between the HRCT score of
emphysema and the number of neutrophils. This finding
seems to support the hypothesis that neutrophils are impli-
cated in the severe stage of COPD, as other studies have also
suggested [29, 30].
Although in COPD patients the two components of airflow
limitation, small airway disease (obstructive bronchiolitis)
and parenchymal destruction (emphysema), often coexist, it
could be clinically relevant to distinguish subjects with
predominant emphysema phenotype.
In conclusion, the authors showed that forced expiratory
volume in one second, chest radiograph score of emphysema
and sputum lymphocytes are the three indices that better
distinguish emphysema from nonemphysema patients. Such
distinction could be useful in clinical practice, may improve
understanding of the natural history of the disease, and may
help to focus treatment strategies for different chronic obstruc-
tive pulmonary disease phenotypes, as, for example, the more
the lung destructive component is widespread, the less anti-
inflammatory drugs are expected to be of benefit.
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